Topical Treatment for Atopic Dermatitis
- Disease/Condition
- Atopic Dermatitis
- Drug/Device/Intervention
- Demonstration of applying triamcinolone cream
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- Wake Forest University Health Sciences
- Location
- Winston-Salem, United States of America
- Phase
- N/A
- Start date
- Apr 01, 2024
- End date
- May 01, 2025
- Enrollment
- 30 participants
Amount of Topical Medication Dispensed - Demonstration Group,Amount of Topical Medication Dispensed - Standard of Care Group,Amount of Topical Medication Dispensed - Mobile Application Group,Number of times of Application - Demonstration Group,Number of times of Application - Standard of Care Group,Number of times of Application - Mobile Application Group,Change in Investigator Global Assessment (IGA) Scores,Change in Percentage of Body Surface Area (BSA) affected,Subject Questionnaire Scores
Medication adherence is a poorly studied phenomenon that challenges both patients and
 physicians. 50% of individuals with chronic disease are not adherent to their medication
 regimen. Within the United States, non-adherence to medical treatment leads to approximately
 $100 billion in hospital admission costs. While the issue of adherence is not limited to any
 particular field of medicine, non-adherence occurs in approximately one-third to one-half of
 dermatological patients. Non-adherence is of importance as it is a significant cause of
 treatment failure, resulting in worse quality of life, worse health outcomes, and increased
 insurance costs.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06244212
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06244212 through Pure Global AI's free database. This phase not specified trial is sponsored by Wake Forest University Health Sciences and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.